Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment.
OBJECTIVE
To explore the cardiac protective effect of integrative therapy in acute myocardial infarction (AMI) with elevated ST segment after reperfusion.


METHODS
Sixty-four AMI patients who having received decimalization by thrombolysis were assigned to two groups by retrospective analysis, 36 patients in the treated group and 28 in the control group. Both were treated by intravenous administering of urokinase for thrombolysis, and to the treated group, intravenous dripping of Xueshuantong Injection (, XST) was added. Serum levels of myocardial associated enzymes were monitored before treatment and at various time points after thrombolysis, and the heart function parameters were detected with color echocardiography before treatment and on the 7th and 14th day of treatment. The patients were followed up for 6 months to observe the incidence of cardiac events.


RESULTS
The differences between groups at the peak and peak appearing time of creatine kinase and creatine kinase isoenzyme were not significant. All the heart function parameters on the 7th and 14th day in the treated group were improved and superior to those at the corresponding time points in the control group (P<0.05, P<0.01). Incidence of some heart events in the treated group within the 6-month follow-up period was lesser than that in the control group (P<0.05).


CONCLUSIONS
XST Injection could provide effective protection for the heart after reperfusion.
Fu
Xiao-xia
XX
The First Traditional Chinese Medicine Hospital of Zhanjiang City, Guangdong, China. Fu_tiger@sina.com
Xiao
Wen-jian
WJ
Lu
Jian
J
Wu
Le-wen
LW
Yang
Fan
F
D052279:Creatine Kinase, MB Form / Q000097:blood; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D004365:Drugs, Chinese Herbal; D052279:Creatine Kinase, MB Form; D014568:Urokinase-Type Plasminogen Activator